With the business potentially at an important milestone, we thought we'd take a closer look at Caris Life Sciences, Inc.'s (NASDAQ:CAI) future prospects. Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. The US$5.2b market-cap company posted a loss in its most recent financial year of US$538m and a latest trailing-twelve-month loss of US$411m shrinking the gap between loss and breakeven. As path to profitability is the topic on Caris Life Sciences' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Consensus from 13 of the American Biotechs analysts is that Caris Life Sciences is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$29m in 2026. Therefore, the company is expected to breakeven roughly 12 months from now or less. We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 73% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Caris Life Sciences given that this is a high-level summary, but, take into account that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

One thing we would like to bring into light with Caris Life Sciences is its relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in Caris Life Sciences' case is 64%. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Caris Life Sciences, so if you are interested in understanding the company at a deeper level, take a look at Caris Life Sciences' company page on Simply Wall St. We've also put together a list of key factors you should look at:

1. Valuation: What is Caris Life Sciences worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Caris Life Sciences is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Caris Life Sciences’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.